Agios Pharmaceuticals Inc. (NASDAQ:AGIO) announced preliminary data on Sunday from its Phase 1 study of AG-221, in patients with advanced hematologic malignancies with an isocitrate dehydrogenase-2 mutation. Agios Pharmaceuticals Inc. (NASDAQ:AGIO) shares after opening at $45.12 moved to $47.65 on last trade day and at the end of the day closed at $46.90. Company price to sales ratio in past twelve months was calculated as 58.10 and price to cash ratio as 8.88. Agios Pharmaceuticals Inc. (NASDAQ:AGIO) showed a positive weekly performance of 25.47%.
Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) announced the presentation of results from an ongoing Phase 1b/2 University of Texas MD Anderson Cancer Center-sponsored trial of vosaroxin in combination with decitabine in older patients with previously untreated acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) shares advanced 0.33% in last trading session and ended the day on $6.05. SNSS return on equity ratio is recorded as 828.70% and its return on assets is -69.20%. Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) yearly performance is 15.90%.
Intrexon Corporation (NYSE:XON) on March 31, 2014, reporting its financial results for the year and quarter ended December 31, 2013. Intrexon Corp (NYSE:XON) shares moved up 5.53% in last trading session and was closed at $23.67, while trading in range of $21.77 – $23.99. Intrexon Corp (NYSE:XON) year to date (YTD) performance is -0.55%.
Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) announced Phase 1 results from a clinical pilot study demonstrating that ferumoxytol*, an iron oxide nanoparticle, was well tolerated when used as a tumor contrast agent prior to MM-398 treatment. Data from the first cohort of patients in this study were presented at the American Association of Cancer Research Annual Meeting, April 5-9, 2014, in San Diego, California. Merrimack Pharmaceuticals Inc. (NASDAQ:MACK) weekly performance is -2.43%. On last trading day company shares ended up $5.22. Merrimack Pharmaceuticals Inc. (NASDAQ:MACK) distance from 50-day simple moving average (SMA50) is 0.04%. Analysts mean target price for the company is $10.90.